Latest cancer therapies Stories
Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.
TORONTO, Nov. 3 /PRNewswire-FirstCall/ -- Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, announced today that Dr. Alan M.
DUBLIN, Calif., Oct. 23 /PRNewswire-FirstCall/ -- SuperGen, Inc.
WALTHAM, Mass., Oct.
Targeted therapies have improved treatment outcomes in cancer notably, becoming the leading therapy class in the oncology market. As a result, they are expected to achieve sales of over $42 billion by 2017.
TORONTO, Sept. 30 /PRNewswire-FirstCall/ -- Bradmer Pharmaceuticals Inc. (TSX: BMR), a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced changes to its Board of Directors.
TORONTO, Aug. 11 /PRNewswire-FirstCall/ -- Bradmer Pharmaceuticals Inc., a clinical oncology company specializing in the development and commercialization of cancer therapies, today announced its 2008 second quarter operational and financial results.
The UK's cost-effectiveness watchdog NICE has delivered another blow to the developers of targeted cancer therapies by recommending against the use of four new kidney cancer drugs in the UK.
TORONTO, July 23 /PRNewswire-FirstCall/ -- July 23, 2008 - Bradmer Pharmaceuticals Inc.
OncoVista Innovative Therapies, Inc.
- The practice of two or more parties jointly purchasing all or part of a butchered cow and dividing the meat between them.